Definium Therapeutics advances pivotal Phase 3 Voyage trial in generalized anxiety disorder

Definium Therapeutics advances pivotal Phase 3 Voyage trial in generalized anxiety disorder
Definium Therapeutics GAD trial advances

Definium Therapeutics has moved forward with its pivotal Phase 3 Voyage trial targeting generalized anxiety disorder (GAD), aiming to set higher expectations for both patients and clinicians in the mental health space.

Chief Executive Officer Robert Barrow shared insights on this milestone, explaining how these results contribute to ongoing efforts to reshape mental health treatment. The company signals this latest achievement as part of its commitment to raising industry standards.

Earlier this year, Definium announced positive Phase 3 data for DT120 ODT in generalized anxiety disorder, reinforcing momentum in its clinical program (Definium Therapeutics advances in pivotal study with fresh Phase 3 anxiety data). The company also delivered its Q2 2026 financials while outlining progress toward new psychiatric disorder treatments (Definium Therapeutics reports Q2 2026 results as momentum builds for psychiatric disorder treatments). These developments form the backdrop for the current Phase 3 Voyage trial in GAD.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.